Search

The article discusses a phase II clinical trial comparing the effects of folate receptor alpha dendritic cells (FRaDCs) to a placebo in treating patients with advanced stage ovarian cancer. FRaDCs are a type of dendritic cell vaccine made from a person's white blood cells and target a protein found in high levels on ovarian tumor cells. The trial aims to evaluate the efficacy of FRaDCs in preventing or delaying recurrence in patients with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer. The study is set to be completed by December 31, 2027, and focuses on outcomes such as recurrence-free survival and overall survival in patients receiving FRaDCs compared to a placebo. [Extracted from the article]

According to a preprint abstract, researchers have identified two genes in the bacteria Bordetella pertussis that are potentially involved in the pathogenesis of whooping cough. These genes, bp1251 and bp1252, encode orphan toxin B subunits that have homology to AB toxin B subunits. Mutations in these genes reduced the adherence of B. pertussis to respiratory epithelial cells in vitro and resulted in lower levels of infection in a mouse model. The findings suggest that these genes may function as novel adhesins and play a significant role in Bordetella infection. However, it is important to note that this research has not yet undergone peer review. [Extracted from the article]

New research from the University of Waterloo in Canada explores the impact of oxidative stress on the growth and productivity of pertactin antigen, a component of the acellular vaccine for whooping cough. The study suggests that variability in initial glutamate concentration, a nutrient in the media, may be a major cause of process variability in the manufacturing of the vaccine. The researchers used cytometry and chromatography-based separation techniques to observe surface expression and quantify extracellular concentration of pertactin. The findings have industrial relevance for improving productivity and reducing process variability. [Extracted from the article]

A report from Vanderbilt University Medical Center in Nashville, Tennessee discusses research findings on whooping cough. The report corrects an erroneous statement made in a recent paper about a newly developed vaccine called BVN008. The statement claimed that BVN008 is identical to the current Tdap vaccines Boostrix and Adacel, but the research clarifies that the acellular pertussis portion of BVN008 was provided by BIKEN in Japan and differs from the compositions of Boostrix and Adacel. The research suggests that a more appropriate statement would be that BVN008 is a booster vaccine similar in concept to Boostrix and Adacel. [Extracted from the article]

A new report from researchers at the University of British Columbia discusses the findings on Bordetella pertussis, the causative agent of whooping cough. The report highlights the differences between acellular and whole-cell pertussis vaccines, with the latter being more effective at preventing colonization and transmission but also more reactogenic. The researchers focused on modifying the lipid A moiety of B. pertussis lipooligosaccharide (LOS) to create an adjuvant strain that could potentially improve the effectiveness of current vaccines and reduce reactogenicity. The study's findings pave the way for the development of less reactogenic whole-cell vaccines and more effective immunization strategies against pertussis. [Extracted from the article]

This article discusses a study that aimed to compare computational models of immunity in predicting the outcomes of B. pertussis vaccination. The study found that the most successful models were those that effectively handled nonlinearities, reduced large feature sets, and utilized advanced data preprocessing techniques. In contrast, models adapted from literature that were developed for predicting vaccine antibody responses in other contexts performed poorly. The study highlights the importance of purpose-built models and purpose-generated datasets for improving the reliability and applicability of computational models in vaccine response prediction. [Extracted from the article]

A recent study on whooping cough, conducted by the Pediatric Unit in Milan, Italy, highlights the global increase in pertussis cases, particularly among infants under three months of age. The study emphasizes the importance of maternal immunization with the Tdap vaccine during pregnancy to protect newborns. Despite the proven benefits of maternal vaccination, coverage rates remain low in many countries due to factors such as vaccine hesitancy, safety concerns, and disruptions caused by the COVID-19 pandemic. The research concludes that increasing vaccine uptake is crucial to reduce the incidence of whooping cough in infants and improve the health outcomes of vulnerable populations. [Extracted from the article]

A recent report from researchers at Sechenov First Moscow State Medical University discusses the severity of whooping cough, a highly contagious respiratory disease that remains endemic in both developing and developed countries despite ongoing vaccination efforts. The study focuses on a clinical observation of a patient with a malignant form of whooping cough, characterized by severe symptoms such as large leukocytosis, refractory hypoxemia, pulmonary hypertension, and cardiopulmonary impairment. The research highlights the importance of factors such as age, immune response, and bacterial dissemination in determining the severity of the disease. For more information, readers can refer to the article "Malignant whooping cough in a palliative patient" published in Kliniceskij razbor v obsej medicine. [Extracted from the article]

Researchers from West Virginia University have conducted a study on Bordetella pertussis, the bacterium responsible for whooping cough. The study focused on the use of the mature C-terminal domain of filamentous hemagglutinin (FHA) as a novel vaccine antigen. The researchers found that the FHA antigen, when conjugated to virus-like particles, was more immunogenic and provided improved protection against B. pertussis infection in mice. These findings support the use of this vaccine platform for the development of vaccines against B. pertussis and other pathogens. The research has been peer-reviewed and published in Infection and Immunity. [Extracted from the article]

A recent study conducted at Bari Aldo Moro University in Southern Italy investigated the acceptance of a pertussis (whooping cough) vaccination campaign among healthcare workers (HCWs) in a large hospital. The study found that prior to the intervention, only 31.34% of the target HCWs had been vaccinated. However, after an active call intervention, vaccine coverage increased to 70.00%. The researchers concluded that the solicitation was effective, suggesting that communication with a trained specialist may have improved the subjects' perception of vaccination and individual risk of contagion and transmission to others. They also suggested that a synergistic approach combining active calls with a vaccination mandate may be more effective. [Extracted from the article]

New research from West Virginia University has found that an mRNA DTP vaccine can protect against pertussis, also known as whooping cough, in rats. The study showed that the mRNA vaccine was immunogenic and induced antigen-specific antibodies comparable to commercially available vaccines. Rats that received the mRNA-DTP vaccine were well protected against coughing and had reduced bacterial burden when challenged with aerosolized B. pertussis. These findings suggest that an mRNA-DTP vaccine could be effective in protecting against pertussis in humans. [Extracted from the article]

A recent study conducted by the Pasteur Institute in France has found a transient reemergence of Bordetella parapertussis, the bacteria responsible for whooping cough, in the country in 2022. This peak in detection was observed between March and October 2022 and was characterized by the presence of the vaccine antigen pertactin in the bacterial isolates collected. The researchers hypothesize that this reemergence may be due to the reintroduction of the bacteria from regions where whole-cell vaccines are still in use. Further research is needed to understand the implications of this finding. [Extracted from the article]

This document provides information about a clinical trial conducted by Minervax ApS. The trial, NCT06494475, aims to evaluate the safety and immunogenicity of a Group B Streptococcus vaccine (GBS-NN/NN2) in combination with a tetanus, diphtheria, and acellular pertussis (Tdap) vaccine. The trial will involve female participants aged 18 to 49 years and will assess the immune response and occurrence of adverse events. The trial is not yet recruiting participants and is expected to be completed by June 21, 2025. The document also includes eligibility criteria and administrative information about the trial. [Extracted from the article]

This article discusses the evolutionary parallelisms between Bordetella parapertussis (Bpp) and Bordetella pertussis (Bp), two pathogens that contribute to whooping cough. The study examines the temporal evolution of Bpp sublineages by sequencing 242 Bpp isolates collected between 1937 and 2019. The researchers found that pertactin deficiency in Bpp was driven by 18 disruptive mutations, including one observed in 73.8% of post-2007 isolates. The study suggests that Bpp has adapted to humans through modulation of the bvgAS regulon and rapid adaptation through the loss of pertactin expression, which coincides with acellular vaccination against whooping cough. [Extracted from the article]

A new report from the Shanghai University of Traditional Chinese Medicine discusses the establishment of an emergency management and epidemiological surveillance system in hospitals to combat pertussis, also known as whooping cough. The researchers highlight the global public health concern posed by the resurgence of pertussis and emphasize the need for a unified surveillance program and effective control strategies. They also suggest considering the role of traditional Chinese medicine in the treatment and prevention of the disease. The research concludes by proposing a model for an emergency management procedure in hospitals to better prepare for future epidemics. [Extracted from the article]

A recent study conducted by the Korea Advanced Institute of Science and Technology (KAIST) in Daejeon, South Korea, focused on the extraction of the outer membrane protein Pertactin (PRN) from Bordetella pertussis, a Gram-negative bacteria responsible for whooping cough. The study aimed to develop a large-scale urea-based process for PRN extraction, which is a crucial component of the acellular pertussis vaccine. The researchers found that freezing and thawing the cell pellet at specific temperatures significantly increased PRN yield, and a 5 M urea treatment for 2 hours was determined to be the optimal condition. The developed extraction process resulted in high-quality PRN with a purity of over 95% at a yield of 33.2%. The findings of this study may have implications for the production of other membrane proteins. [Extracted from the article]

A recent study conducted by researchers at the University of Kansas focused on the introduction of new recombinant protein antigens to existing pediatric combination vaccines, specifically in low- and middle-income countries (LMICs). The study examined the compatibility of three recombinant non-replicating rotavirus vaccine (NRRV) antigens with a mock multidose formulation of a pediatric pentavalent vaccine. The researchers found that simple mixing led to the desorption of the NRRV antigens and increased degradation during storage, which was caused by specific antigens, aluminum-salt adjuvants, and a preservative. The study provides insights for future formulation development of combination vaccines with new vaccine candidates. [Extracted from the article]

Researchers from Debre Markos University in Ethiopia conducted a systematic review and meta-analysis to investigate the attack rate, case fatality rate, and predictors of pertussis outbreaks in Ethiopia. They analyzed seven outbreak investigations with a total of 2,824 cases and 18 deaths. The study found that the pooled attack rate was 10.78 per 1,000 population, and the case fatality rate was 0.8%. Being unvaccinated and having contact history were identified as predictors of contracting pertussis. The researchers recommend strengthening routine vaccination and contact tracing efforts to prevent future outbreaks. [Extracted from the article]

A new report from researchers at the University of Brasilia provides insights into a whooping cough outbreak in the Brazilian Midwest region. The outbreak occurred despite high vaccination coverage, and the researchers found that the circulating strains of Bordetella pertussis, the bacteria that causes whooping cough, were different from the strain used in the vaccine. The most prevalent genotype associated with the outbreak was fim3-24/ptxP-3. These findings could help inform future vaccination programs to prevent similar outbreaks in Brazil. [Extracted from the article]

A new study conducted by researchers at West Virginia University has found that multivalent mRNA-DTP vaccines are immunogenic and provide protection against Bordetella pertussis infection in mice. The study utilized immunization and challenge models to evaluate the mRNA platform with multivalent vaccine formulations targeting B. pertussis antigens, as well as diphtheria and tetanus toxoids. The mRNA DTP vaccines induced antigen-specific antibodies and Th1 T cell responses, and provided protection equal to that of human doses of DTaP or whole cell pertussis vaccines. These findings suggest that the mRNA platform has potential for developing multivalent bacterial pathogen vaccines. [Extracted from the article]

A patent application has been submitted by researchers from nference Inc. for a method of identifying patient populations vulnerable to viral infection and inducing heterologous immunity. The method involves analyzing patient-specific data to assess the cross-protective effects of existing vaccines against SARS-COV-2 infection. By determining demographic covariates and propensity scores, the researchers aim to reduce the risk of acquiring or fully presenting a disease case by SARS-COV-2 infection. The method also involves administering vaccines that have not been given to the subject within the past year. Ongoing clinical trials are investigating the potential protective effects of existing vaccines against COVID-19 infection. [Extracted from the article]

ModernaTX Inc. has filed a patent application for a ribonucleic acid (RNA) vaccine that targets whooping cough, diphtheria, and tetanus. The vaccine uses messenger RNA (mRNA) to instruct the body to produce specific proteins that can fight these diseases. The vaccine contains multiple mRNA polynucleotides that encode various antigenic polypeptides for Bordetella pertussis. It has the potential to treat and prevent infections caused by different strains and genotypes of these diseases. The patent application includes claims for different compositions of the vaccine, as well as specific amino acid and nucleotide sequences for the antigenic polypeptides. [Extracted from the article]

A recent study conducted by investigators from EpiConcept in Paris, France, examined the effectiveness of pertussis vaccines in infants. The study utilized data from the Pertussis in Infants European Network (PERTINENT), a surveillance system implemented in 35 hospitals across six EU/EEA countries. The researchers found that the adjusted effectiveness of at least one dose of the vaccine was 59%, with a lower effectiveness of 48% for the first dose and a higher effectiveness of 76% for the second dose. The study suggests that larger sample sizes would provide more precise estimates for the effectiveness of each dose. [Extracted from the article]

A recent study conducted by researchers from the University of Maryland examined the safety and immunogenicity of a single dose of the tetanus, diphtheria, and acellular pertussis vaccine (Tdap) compared to the tetanus and diphtheria vaccine (Td) in pregnant women in Mali. The study found that Tdap administered to pregnant women in Mali was safe and well-tolerated, and infants born to mothers who received Tdap had high levels of pertussis toxin (PT) and protective anti-tetanus toxin (TT) antibodies. However, the study also noted that the immune responses to primary pertussis vaccination in infants born to mothers who received Tdap were blunted, indicating a need for further research. [Extracted from the article]

A patent application has been submitted for the approval of "Self-Assembling Nanostructure Vaccines." The inventors propose nanostructure-based vaccines as a new approach to increase the potency and breadth of the immune response. These vaccines utilize nanostructures composed of polypeptides and antigens arranged in symmetrically ordered arrays. The nanostructures can be used to generate immunity to infectious agents and elicit a neutralizing antibody response. Methods of making the nanostructures through in vitro assembly or co-expression in recombinant expression systems are also described. This patent application describes a method for creating nanostructures that can be used as vaccines to generate immunity against various infectious agents. The nanostructures consist of polypeptides arranged in a specific pattern and attached to antigens. The antigens can be proteins or fragments of proteins from different infectious agents such as HIV, influenza, Ebola, and malaria. The method involves expressing the polypeptides and antigens in a recombinant expression system, purifying them, and then mixing them to generate the nanostructure. The resulting vaccine can elicit a broadly-neutralizing immune response. [Extracted from the article]

A recent study conducted by researchers from the University of Novi Sad in Serbia examined the epidemiological characteristics of pertussis, also known as whooping cough, in the Autonomous Province of Vojvodina. The study analyzed data from 1948 to 2023 and found that the reported incidence of pertussis declined after the introduction of the DTwP vaccine in 1960. However, since 2012, there has been an increase in pertussis cases, particularly among school-aged children. The researchers recommend introducing additional booster doses of the aP vaccine for individuals aged 14 years and implementing maternal immunization strategies. [Extracted from the article]

A recent study conducted by researchers from the University of Copenhagen aimed to review the current evidence on immunity against tetanus, diphtheria, and pertussis in adult solid organ transplantation (SOT) recipients. The study found that SOT recipients initially exhibit considerable immunity against tetanus and diphtheria, but this immunity decreases over time. Vaccination can enhance this immunity, but the response may be suboptimal and the increased antibody levels may not persist. The findings highlight the need for tailored vaccination strategies in this vulnerable population. [Extracted from the article]

A recent study conducted by the National Research Council of Canada explores the potential of outer membrane vesicles derived from Bordetella pertussis (OMVBp) as a third-generation vaccine against pertussis. The study found that OMVBp exhibits adjuvant properties, enhancing the immune response even at low concentrations. Additionally, OMVBp was shown to skew the immune response towards a Th1 profile. These findings suggest that OMVBp could be incorporated into combined vaccine formulations. [Extracted from the article]

A new report from the Statens Serum Institute in Denmark reveals a record high pertussis (whooping cough) epidemic in the country since August 2023. The highest incidence of the disease was found in adolescents, while the peak incidence in infants was lower compared to previous epidemics. However, among infants aged 0-2 months, over half were hospitalized and one infant died, highlighting the severity of the disease in the youngest age group. To protect infants, pertussis vaccination in pregnant women was introduced in January 2024 as part of the national vaccination program, and improved vaccination surveillance in pregnant women is being implemented. [Extracted from the article]

A patent has been issued to nference Inc. for a method of identifying patient populations vulnerable to viral infection and inducing heterologous immunity. The patent describes the use of existing vaccines to reduce the risk of SARS-CoV-2 infection. By analyzing patient-specific data and administering the appropriate vaccines, the risk of acquiring or fully presenting a disease case by SARS-CoV-2 infection can be reduced. The patent discusses methods for reducing the risk of SARS-CoV-2 infection by administering vaccines to individuals who have not received certain vaccines within a specified time frame. The goal is to induce a heterologous immune response to SARS-CoV-2 infection. [Extracted from the article]

A systematic review and meta-analysis conducted by researchers at the ICMR-National Institute of Virology in Pune, India, examined the effectiveness of pertussis vaccines in protecting children against Bordetella parapertussis infection. The analysis, which included 46,533 participants, found no significant protective effect of pertussis vaccination against B. parapertussis infection. The researchers concluded that the lack of effectiveness of current vaccines against B. parapertussis highlights the need for the development of vaccines with specific antigens to protect against this strain. The study emphasizes the urgency of further research in this area due to the rising incidence of cases and outbreaks. [Extracted from the article]

A recent report from researchers at Nagasaki University discusses the prevalence of whooping cough in Vietnam. The study conducted two surveys in different regions of Vietnam to investigate recent pertussis infection and associated factors. The results showed that pertussis circulation is present across all age groups in both high- and low-vaccine-coverage areas in Vietnam, highlighting the importance of continuous surveillance for a comprehensive understanding of the disease's epidemiology. The study also found that certain factors, such as cough, recent antibiotic use, and smoking, were associated with higher levels of pertussis infection. [Extracted from the article]

A patent application has been filed for a method of producing increased amounts of native outer membrane vesicles (nOMV) in Gram-negative bacteria. These nOMV can be used in the development of vaccines. The inventors have discovered that modifications to the rpsA gene, rpsA operon, and/or 30S ribosomal protein S1 can induce a hyper-blebbing phenotype in the bacteria, resulting in increased nOMV production. This method offers advantages over previous methods that involved disrupting genes encoding membrane structural components. The genetically modified bacteria are capable of secreting greater quantities of nOMV, which could be beneficial for vaccine production. [Extracted from the article]

A patent application has been submitted for a method to enhance the effectiveness and safety of vaccines by using an interleukin-4 receptor (IL-4R) antagonist in combination with the vaccine. The goal of this invention is to improve the immune response to vaccines, prolong the protection provided by vaccines, prevent the spread of diseases, and reduce allergic reactions. The IL-4R antagonist can also be used to treat atopic dermatitis without interfering with the vaccine's effectiveness. The patent application covers a wide range of diseases and infections that can be targeted with the vaccine. The methods described in the application involve administering the IL-4R antagonist before, after, or at the same time as the vaccine, in various doses and frequencies. The vaccine can be used against bacterial and viral infections such as pertussis, diphtheria, tetanus, tuberculosis, influenza, and hepatitis. The aim of these methods is to enhance the T helper 1 immune response to the vaccine, which is beneficial for certain individuals. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the use of outer membrane vesicles (OMVs) derived from Bordetella pertussis as a potential immunogen for improving pertussis vaccines. The study evaluates different mucosal administration strategies in a murine model, including homologous and heterologous schedules, and compares them to commercial vaccines. The results show that the use of OMVs, particularly through intranasal administration, outperformed acellular pertussis vaccines in reducing bacterial colonization in the upper respiratory tract. The study also explores the use of different adjuvants but finds that alum did not enhance the immune protective capacity. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

A recent study conducted by researchers at Radboud University Medical Center explores the immune response to the Bordetella pertussis bacteria, which causes whooping cough. The study focuses on the effectiveness of the tetanus-diphtheria-acellular pertussis-inactivated poliovirus (Tdap-IPV) vaccine in promoting durable protection against pertussis. The researchers found that early antiviral and interferon gene expression in the blood correlated with persistent antibody responses to pertussis. Additionally, they discovered that the Tdap-IPV vaccine stimulated stronger antiviral responses compared to the Tdap vaccine alone. These findings provide valuable insights into the molecular host response to pertussis booster vaccination and highlight the potential benefits of the Tdap-IPV vaccine in enhancing immune activity and promoting long-lasting immunity. [Extracted from the article]

A study conducted by investigators at Maastricht University in the Netherlands aimed to promote informed decision-making about maternal pertussis vaccination (MPV) in pregnant individuals. The researchers developed a group-antenatal care intervention called Centering Pregnancy (CP) to discuss MPV within existing group-care settings. The study found that the CP intervention was implemented as intended in most groups and was positively evaluated by participants and facilitators. However, the intervention could be improved by discussing MPV earlier in pregnancy. The researchers concluded that a larger-scale study is needed to assess the effects of the intervention on MPV uptake and informed decision-making. [Extracted from the article]

A recent study conducted at Eskisehir City Hospital in Turkey examined the levels of pertussis antibodies in pregnant women and umbilical cord blood. The study found that the majority of pregnant women and cord blood samples had anti-pertussis toxin (PT) levels below 40 IU/mL. This is concerning because pertussis can cause serious illness and death in infants, and vaccination of pregnant women is an effective way to prevent it. The study highlights the low rates of pertussis vaccination among pregnant women and the need for increased immunization efforts. [Extracted from the article]

A recent study conducted at West Virginia University explored the effectiveness of different pertussis vaccines in preventing whooping cough. The researchers investigated the use of a novel adjuvant called BECC438b and compared the immune responses generated by intramuscular (IM) and intranasal (IN) administration of the vaccines in mice. The results showed that the addition of BECC438b reduced bacterial burden in the lungs and trachea of the mice, and IN administration induced a Th1-polarized immune response while IM vaccination polarized towards a Th2 immune response. These findings suggest that the BECC438b adjuvant and the IN vaccination route could impact the efficacy and immune responses of pertussis vaccines. [Extracted from the article]

A new study conducted by the La Jolla Institute for Immunology explores the T cell reactivity to Bordetella pertussis, the bacteria that causes whooping cough. The study found that T cell responses to the bacteria were highly diverse in vaccinated adults, regardless of childhood vaccination. The research suggests that asymptomatic infections may drive the pattern of T cell reactivity in adults. These findings provide insights into human T cell responses to Bordetella pertussis and could inform the development of next-generation pertussis vaccines. The study was supported by the NIH National Institute of Allergy & Infectious Diseases. [Extracted from the article]

A recent report from the Instituto de Biotecnologia y Biologia Molecular highlights the global challenge of pertussis, also known as whooping cough. The incidence of pertussis cases has been increasing in recent years, posing a significant risk to newborns and infants. Vaccination during pregnancy has emerged as an important strategy to prevent infection in pregnant individuals and reduce the impact of the disease. The report summarizes the current state of pertussis vaccination in pregnancy worldwide, providing recommendations for improved care and addressing vaccination challenges for healthcare providers. [Extracted from the article]

A new report from the Catholic University of Korea presents fresh data on whooping cough. The research compares the immunogenicity and protective efficacy of two different pertussis vaccines in a murine model. The study found that the recombinant aP (raP) vaccine exhibited strong antibody responses and provided a sterile lung bacterial clearance comparable to a commercial control vaccine. The researchers suggest that the raP vaccine has the potential to be an effective alternative to acellular pertussis (aP) vaccines for controlling pertussis outbreaks. [Extracted from the article]

The article provides information on the reporting requirements for adverse events following vaccine administration, as mandated by the National Childhood Vaccine Injury Act (NCVIA). Healthcare providers are required to report specific events, and vaccine manufacturers must also report adverse experiences to the FDA. The article emphasizes the safety and effectiveness of vaccines and highlights the success of immunization programs in reducing vaccine-preventable diseases. The CDC supports state governments in enacting and enforcing immunization laws, and exemptions for vaccination requirements vary among states. Vaccinations have been effective in reducing the incidence of diseases, and high vaccination rates contribute to "herd immunity." Adverse event information can be obtained through a Freedom of Information Act (FOIA) request with the FDA, and vaccine expiration dates can be extended based on data submitted to the FDA by the manufacturer. [Extracted from the article]

A recent study conducted by GlaxoSmithKline (GSK) Vaccines explored the safety and immunogenicity of a respiratory syncytial virus (RSV) prefusion maternal vaccine. The study involved healthy, nonpregnant women who were randomized into five groups and received different combinations of the RSV vaccine and a diphtheria-tetanus-pertussis vaccine (dTpa). The results showed that the RSV vaccine was well-tolerated and induced robust immune responses, regardless of the dose level or coadministration with dTpa. The findings suggest that this combination could be a promising approach for preventing RSV infection. The study is registered under Clinical Trials Registration NCT04138056. [Extracted from the article]

A recent study compared the immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule to the standard acellular pertussis-only schedule in Australian infants. The study found that the mixed schedule was associated with more reactions, although mostly non-severe, compared to the acellular pertussis-only schedule. However, the mixed schedule was well accepted by parents and showed non-inferior immune responses after completion of the three-dose primary series. The study was funded by the Telethon New Children's Hospital Research Fund and the National Health and Medicine Research Council. [Extracted from the article]

A meta-analysis and modeling study examined the impact of maternal pertussis immunization on the effectiveness of routine vaccination. The study found that while maternal immunization successfully reduces pertussis in infants, it may also erode the effectiveness of primary vaccination at later ages due to immunological blunting. The evidence from the study suggests that there may be modest reductions in the effectiveness of primary vaccination, but maternal immunization remains effective at protecting unvaccinated newborns. The study emphasizes the need for further research and supports current public health recommendations. [Extracted from the article]

A recent study conducted by the National Center for Immunization and Respiratory Diseases in Atlanta, Georgia, explores the potential for developing a more effective vaccine for whooping cough. The researchers aimed to identify vaccine antigens that could provide cross-protective immunity against multiple Bordetella pathogens. Through genomic analysis and immunoinformatics, they identified a list of peptides that may confer long-lasting T-cell immunity. This research has important implications for improving the efficacy of pertussis vaccines and protecting against other species that cause pertussis-like illness. [Extracted from the article]